vs
LXP Industrial Trust（LXP）与帕可Bio（PACB）财务数据对比。点击上方公司名可切换其他公司
LXP Industrial Trust的季度营收约是帕可Bio的1.9倍（$86.7M vs $44.6M），LXP Industrial Trust净利率更高（33.2% vs -90.4%，领先123.6%），帕可Bio同比增速更快（13.8% vs -14.0%），过去两年帕可Bio的营收复合增速更高（7.3% vs 0.3%）
LXP工业信托是一家公开上市的房地产投资信托，专注于持有、运营和投资美国核心市场的优质工业地产，主要涵盖配送中心、物流设施及轻型工业物业，服务电商、第三方物流、先进制造等领域租户，为投资者创造长期稳定收益。
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
LXP vs PACB — 直观对比
营收规模更大
LXP
是对方的1.9倍
$44.6M
营收增速更快
PACB
高出27.8%
-14.0%
净利率更高
LXP
高出123.6%
-90.4%
两年增速更快
PACB
近两年复合增速
0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.7M | $44.6M |
| 净利润 | $28.8M | $-40.4M |
| 毛利率 | 81.5% | 37.1% |
| 营业利润率 | 34.6% | -92.3% |
| 净利率 | 33.2% | -90.4% |
| 营收同比 | -14.0% | 13.8% |
| 净利润同比 | — | -1802.7% |
| 每股收益（稀释后） | — | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LXPPACB
| Q4 25 | $86.7M | $44.6M | ||
| Q3 25 | $86.9M | $38.4M | ||
| Q2 25 | $87.7M | $39.8M | ||
| Q1 25 | $88.9M | $37.2M | ||
| Q4 24 | $100.9M | $39.2M | ||
| Q3 24 | $85.6M | $40.0M | ||
| Q2 24 | $85.8M | $36.0M | ||
| Q1 24 | $86.3M | $38.8M |
净利润LXPPACB
| Q4 25 | $28.8M | $-40.4M | ||
| Q3 25 | $36.3M | $-38.0M | ||
| Q2 25 | $29.1M | $-41.9M | ||
| Q1 25 | $19.0M | $-426.1M | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | $6.3M | $-60.7M | ||
| Q2 24 | $5.4M | $-173.3M | ||
| Q1 24 | $-269.0K | $-78.2M |
毛利率LXPPACB
| Q4 25 | 81.5% | 37.1% | ||
| Q3 25 | 82.3% | 41.4% | ||
| Q2 25 | 81.9% | 36.9% | ||
| Q1 25 | 80.7% | -3.7% | ||
| Q4 24 | 85.3% | 25.6% | ||
| Q3 24 | 82.5% | 25.0% | ||
| Q2 24 | 82.0% | 16.5% | ||
| Q1 24 | 82.4% | 29.1% |
营业利润率LXPPACB
| Q4 25 | 34.6% | -92.3% | ||
| Q3 25 | 50.4% | -101.1% | ||
| Q2 25 | 33.7% | -112.8% | ||
| Q1 25 | 21.8% | -1154.5% | ||
| Q4 24 | — | -390.1% | ||
| Q3 24 | 7.9% | -160.3% | ||
| Q2 24 | 6.9% | -488.3% | ||
| Q1 24 | 1.0% | -209.6% |
净利率LXPPACB
| Q4 25 | 33.2% | -90.4% | ||
| Q3 25 | 41.7% | -98.9% | ||
| Q2 25 | 33.2% | -105.4% | ||
| Q1 25 | 21.4% | -1146.8% | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | 7.4% | -151.9% | ||
| Q2 24 | 6.3% | -481.3% | ||
| Q1 24 | -0.3% | -201.4% |
每股收益（稀释后）LXPPACB
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $0.12 | $-0.13 | ||
| Q2 25 | $0.09 | $-0.14 | ||
| Q1 25 | $0.06 | $-1.44 | ||
| Q4 24 | — | $-0.44 | ||
| Q3 24 | $0.02 | $-0.22 | ||
| Q2 24 | $0.01 | $-0.64 | ||
| Q1 24 | $-0.01 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $170.4M | $279.5M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $2.0B | $5.3M |
| 总资产 | $3.5B | $784.1M |
| 负债/权益比越低杠杆越低 | 0.66× | — |
8季度趋势，按日历期对齐
现金及短期投资LXPPACB
| Q4 25 | $170.4M | $279.5M | ||
| Q3 25 | $229.7M | $298.7M | ||
| Q2 25 | $71.0M | $314.7M | ||
| Q1 25 | $70.9M | $343.1M | ||
| Q4 24 | $101.8M | $389.9M | ||
| Q3 24 | $55.0M | $471.1M | ||
| Q2 24 | $48.7M | $509.8M | ||
| Q1 24 | $293.8M | $561.9M |
总债务LXPPACB
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LXPPACB
| Q4 25 | $2.0B | $5.3M | ||
| Q3 25 | $2.1B | $36.1M | ||
| Q2 25 | $2.1B | $61.5M | ||
| Q1 25 | $2.1B | $91.6M | ||
| Q4 24 | $2.1B | $506.6M | ||
| Q3 24 | $2.1B | $453.1M | ||
| Q2 24 | $2.1B | $492.7M | ||
| Q1 24 | $2.2B | $649.0M |
总资产LXPPACB
| Q4 25 | $3.5B | $784.1M | ||
| Q3 25 | $3.7B | $803.2M | ||
| Q2 25 | $3.7B | $825.5M | ||
| Q1 25 | $3.8B | $860.8M | ||
| Q4 24 | $3.8B | $1.3B | ||
| Q3 24 | $3.9B | $1.5B | ||
| Q2 24 | $3.9B | $1.5B | ||
| Q1 24 | $4.2B | $1.7B |
负债/权益比LXPPACB
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $188.7M | $-19.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-19.9M |
| 自由现金流率自由现金流/营收 | — | -44.6% |
| 资本支出强度资本支出/营收 | — | 1.9% |
| 现金转化率经营现金流/净利润 | 6.56× | — |
| 过去12个月自由现金流最近4个季度 | — | $-114.1M |
8季度趋势，按日历期对齐
经营现金流LXPPACB
| Q4 25 | $188.7M | $-19.1M | ||
| Q3 25 | $63.5M | $-18.7M | ||
| Q2 25 | $44.3M | $-29.4M | ||
| Q1 25 | $39.0M | $-44.1M | ||
| Q4 24 | $211.2M | $-30.6M | ||
| Q3 24 | $64.6M | $-45.5M | ||
| Q2 24 | $38.5M | $-54.3M | ||
| Q1 24 | $38.9M | $-75.7M |
自由现金流LXPPACB
| Q4 25 | — | $-19.9M | ||
| Q3 25 | — | $-18.8M | ||
| Q2 25 | — | $-29.9M | ||
| Q1 25 | — | $-45.4M | ||
| Q4 24 | — | $-32.3M | ||
| Q3 24 | — | $-46.3M | ||
| Q2 24 | — | $-55.7M | ||
| Q1 24 | — | $-79.6M |
自由现金流率LXPPACB
| Q4 25 | — | -44.6% | ||
| Q3 25 | — | -48.9% | ||
| Q2 25 | — | -75.3% | ||
| Q1 25 | — | -122.3% | ||
| Q4 24 | — | -82.3% | ||
| Q3 24 | — | -115.7% | ||
| Q2 24 | — | -154.8% | ||
| Q1 24 | — | -205.0% |
资本支出强度LXPPACB
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | 10.0% |
现金转化率LXPPACB
| Q4 25 | 6.56× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 2.05× | — | ||
| Q4 24 | — | -12.93× | ||
| Q3 24 | 10.18× | — | ||
| Q2 24 | 7.09× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LXP
暂无分部数据
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
